ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

July 3, 2020

Study Completion Date

September 29, 2020

Conditions
Clostridium Difficile Infection
Interventions
BIOLOGICAL

SER-109

"SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors~Other Names:~Eubacterial Spores, Purified Suspension, Encapsulated"

DRUG

Placebo

Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline(0.9%).

Trial Locations (56)

14215

(Investigator site), Buffalo

15213

(Investigator site), Pittsburgh

18840

(Investigator site), Sayre

20007

(Investigator site), Washington D.C.

20191

(Investigator site), Reston

20814

(Investigator site), Chevy Chase

21401

(Investigator site), Annapolis

22908

(Investigator site), Charlottesville

27607

(Investigator site), Raleigh

27834

(Investigator site), Greenville

28501

(Investigator site), Kinston

30060

(Investigator site), Marietta

30274

(Investigator site), Riverdale

30322

(Investigator site), Atlanta

30342

(Investigator site), Sandy Springs

30607

(Investigator site), Athens

32256

(Investigator site), Jacksonville

33015

(Investigator site), Miami

33024

(Investigator site), Pembroke Pines

33026

(Investigator site), Pembroke Pines

33155

(Investigator site), Miami

43215

(Investigator site), Columbus

44195

(Investigator site), Cleveland

45459

(Investigator site), Centerville

47130

(Investigator site), Jeffersonville

47714

(Investigator site), Evansville

48073

(Investigator site), Royal Oak

48202

(Investigator site), Detroit

52242

(Investigator site), Iowa City

59701

(Investigator site), Butte

62703

(Investigator site), Springfield

63141

(Investigator site), St Louis

66160

(Investigator site), Kansas City

70121

(Investigator site), New Orleans

72117

(Investigator site), North Little Rock

76092

(Investigator site), Southlake

77098

(Investigator site), Houston

78234

(Investigator site), San Antonio

83404

(Investigator site), Idaho Falls

84010

(Investigator site), Bountiful

84065

(Investigator site), Riverton

89119

(Investigator site), Las Vegas

91324

(Investigator site), Northridge

91786

(Investigator site), Upland

93065

(Investigator site), Simi Valley

94040

(Investigator site), Mountain View

95655

(Investigator site), Mather

95817

(Investigator site), Sacramento

06518

(Investigator site), Hamden

02144

(Investigator site), Boston

01655

(Investigator site), Worcester

T2N 2T9

(Investigator site), Calgary

V5Z 1M9

(Investigator site), Vancouver

V8R 1J8

(Investigator site), Victoria

N6A 4V2

(Investigator site), London

G7H 7Y8

(Investigator site), Chicoutimi

All Listed Sponsors
lead

Seres Therapeutics, Inc.

INDUSTRY

NCT03183128 - ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection | Biotech Hunter | Biotech Hunter